Expedited Process Agreement Background/Overview:Expedited Process Agreement • November 23rd, 2020
The Harvard Medical School (“HMS”) received a grant from the National Institutes of Health (the “Grant”) to form a new repository of plasmids (the “Repository”) to store, maintain, and facilitate the collection and exchange of plasmids (the “Plasmids”) among researchers at academic, profit, and non-profit institutions for non-commercial, basic biological and biomedical research. Plasmids were shared with HMS by researchers at one or more institutions (each, a “Depositor Institution”) for distribution in accordance with a Standard Material Transfer Agreement. HMS has established a process, which is more fully detailed below, to effectuate the most efficient distribution of the Plasmids. An institution wishing to be eligible to receive Plasmids from the Repository (a “Recipient Institution”) by this more efficient distribution process is required to complete and submit this document to HMS.
Biological Material Transfer AgreementMaterial Transfer Agreement • July 27th, 2009
In response to the RECIPIENT’s request for certain plasmids known as FLEXGene Clones (“MATERIALS”), President and Fellows of Harvard College (“HARVARD”) requires that RECIPIENT agree to the following before the RECIPIENT receives the MATERIALS.
PLASMID DEPOSIT AGREEMENTPlasmid Deposit Agreement • April 8th, 2008 • New York
THIS PLASMID DEPOSIT AGREEMENT (the “Agreement”), effective as of , 2007 (the “Effective Date”), is entered into by and between XXX, an academic institution, non- profit organization, for-profit company at ADDRESS (the “Depositor Institution”), and President and Fellows of Harvard College on behalf of Harvard’s Institute of Proteomics (“HIP”), located at 320 Charles St., Cambridge, MA 02141 (“Harvard”) each individually referred to as a “Party” and collectively referred to as the “Parties”.
Expedited Process Agreement Background/Overview:Expedited Process Agreement • August 4th, 2009
The Harvard Medical School (“HMS”) received a grant from the National Institutes of Health (the “Grant”) to form a new repository of plasmids (the “Repository”) to store, maintain, and facilitate the collection and exchange of plasmids (the “Plasmids”) among researchers at academic, profit, and non-profit institutions for non-commercial, basic biological and biomedical research. Plasmids were shared with HMS by researchers at one or more institutions (each, a “Depositor Institution”) for distribution in accordance with a Standard Material Transfer Agreement. HMS has established a process, which is more fully detailed below, to effectuate the most efficient distribution of the Plasmids. An institution wishing to be eligible to receive Plasmids from the Repository (a “Recipient Institution”) by this more efficient distribution process is required to complete and submit this document to HMS.
Biological Material Transfer AgreementMaterial Transfer Agreement • July 23rd, 2009
In response to the Recipient’s ACCEPTENCE of FLEXGene clones the recipient stipulates to having read and agrees to the following:
Standard Plasmid Transfer AgreementPlasmid Transfer Agreement • March 10th, 2010
Standard Plasmid Transfer Agreement is by and among you ("Recipient Institution" or "You"), and the President and Fellows of Harvard College on behalf of the Harvard Medical School (“HMS”). You are being provided with Plasmids that were developed by researchers (“Depositor Scientists”) working at one or more originating institutions (each, a “Depositor Institution”). The Depositor Institutions are the beneficiaries of, and may independently enforce, this Agreement. The Plasmids, together with any replicas and unmodified derivatives thereof, shall be referred to as the “Plasmids.”
